1. Home
  2. KALV vs QDEL Comparison

KALV vs QDEL Comparison

Compare KALV & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.99

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$13.90

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
QDEL
Founded
N/A
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2014
2022

Fundamental Metrics

Financial Performance
Metric
KALV
QDEL
Price
$26.99
$13.90
Analyst Decision
Strong Buy
Hold
Analyst Count
5
4
Target Price
$32.60
$28.25
AVG Volume (30 Days)
3.0M
1.8M
Earning Date
07-09-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.35
EPS
N/A
N/A
Revenue
$50,000,000.00
$2,730,200,000.00
Revenue This Year
$185.42
$3.51
Revenue Next Year
$59.23
$3.86
P/E Ratio
N/A
N/A
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$9.92
52 Week High
$27.00
$35.58

Technical Indicators

Market Signals
Indicator
KALV
QDEL
Relative Strength Index (RSI) 75.79 54.63
Support Level $14.22 $10.39
Resistance Level N/A $15.76
Average True Range (ATR) 0.03 1.04
MACD -0.23 0.19
Stochastic Oscillator 95.83 50.94

Price Performance

Historical Comparison
KALV
QDEL

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

Share on Social Networks: